Related Experiment Videos
[Autoantibodies against advanced glycation products in patients with type 1 diabetes mellitus]
M González1, C Paquién, S Asenjo
1Departamento de Bioquímica Clínica e Inmunología, Facultad de Farmacia, Universidad de Concepción, Casilla 237, Concepción, Chile. magonzal@udec.cl
Background:
Advanced glycation end products are associated with chronic complications of diabetes mellitus. This glycation process renders many proteins immunogenic.
Aim:
To detect the presence of antibodies against albumin, collagen and low density lipoprotein glycation products in boys and teenagers with diabetes mellitus.
Patients And Methods:
Thirty one patients with diabetes mellitus type I, aged 11 +/- 3.8 years and with a mean duration of disease of 3.7 +/- 2.7 years and 31 healthy controls aged 12.4 +/- 5.3 years were studied. Antibodies against glycation end products were detected by ELISA and results were expressed as a ratio of the optical density of the glycated protein/optical density of the native protein.
Results:
Diabetic patients and healthy controls did not have antibodies against albumin glycation end products. Diabetics had higher levels of antibodies than controls for collagen glycation end products (2.6 +/- 0.4 and 1.8 +/- 0.2 respectively, p < 0.01) and low density lipoprotein glycation end products (3.07 +/- 0.92 and 2.2 +/- 0.72 respectively, p < 0.05).
Conclusions:
The biological role of these antibodies is not clear. They could be a depuration mechanism for glycation end products or contribute to chronic complications of diabetes mellitus.